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Kresoxim-methyl was one of the two first strobilurins to be discovered, and nowadays it is widely used as antifungal agent in crop 
protection. Because of its low molecular weight and little structural complexity, generation of antibodies to kresoxim-methyl noticeably 
requires the preparation of functionalized haptens. In this study, the introduction of a hydrocarbon spacer arm at aromatic moieties of the 
target molecule was carried out by a convergent strategy based on the Sonogashira cross-coupling reaction, and functionalized linkers of 10 
the same length were also tethered to the aliphatic toxophore group by O-alkylation reaction. Evaluation of the immune response, in 
terms of antibody affinity, showed a differential behavior among five synthesized haptens whose sole dissimilarity was the derivatization 
site. The characteristic (methoxyimino)acetate moiety of strobilurins was revealed as the optimum linker position for high-affinity 
polyclonal and monoclonal antibody production. However, good monoclonal antibodies were isolated from mice immunized with a 
hapten carrying the linker at an opposite site, which otherwise generated a poor polyclonal response in rabbits. Site-heterology was 15 
confirmed as a feasible approach for the improvement of the apparent affinity, particularly with polyclonal antibodies. Several of the 
monoclonal antibodies generated in the context of this project could be proper binders for kresoxim-methyl immunosensing over 
different analytical platforms. 
Introduction 
Strobilurins are one of the most important families of modern 20 
crop protection compounds. Their invention was made possible 
after the discovery and chemical description, by Anke and 
coworkers in 1977,1 of strobilurin A – a natural antibiotic 
derivative of β-methoxyacrylic acid that was isolated from 
Strobilurus tenacellus and Oudemansiella mucida. More recently, 25 
it was discovered that strobilurins are also produced by other 
genera, such as Xerula, Hydropus, Mycena, Filoboletus, 
Crepidotus, Cyphellopsis, and Bolinea.2 However, the naturally 
secreted product is not stable to light and therefore not useful for 
pest control. All currently registered strobilurins – 19 so far – are 30 
synthetic nature-derived chemicals, which are comprised of a 
common aromatic bridge that provides photochemical stability to 
the molecule and holds both the toxophore moiety and a 
distinctive bulky substituent in ortho position.3 Kresoxim-methyl, 
which was released in the mid 1990’s by BASF, belongs to the 35 
first-generation of strobilurins. Structurally, kresoxim-methyl is 
characterized by a methyl (E)-2-(methoxyimino)-2-phenylacetate 
group (a-ring), which holds the toxophore moiety responsible of 
its biocide activity and an o-tolyl group (b-ring) – both rings 
being joined together by means of a methylidenoxy group (Fig. 40 
1). At 20 °C, kresoxim-methyl is a white solid with low solubility 
in water (2 mg L−1) and low volatility (vapor pressure of 1.72 × 
10−8 mm Hg), and it is highly photostable showing a half-life 
time of 30 days. The synthetic pathway to prepare this molecule 
has evolved from the first procedure described by Wenderoth et 45 
al. in 1989,4 which implied several synthetic steps for the 
construction of the (methoxyimino)acetate moiety, to more recent 
strategies based on the Suzuki–Miyaura coupling reaction that 
allow the stereoselective construction of the 
(E)-2-(methoxyimino)-2-phenylacetate moiety with high yield in 50 
only one synthetic step.5 
 Antibody-based techniques constitute nowadays valuable 
alternative strategies for small organic chemical monitoring. In 
particular, antibodies recognizing modern and relevant pesticides 
are deemed valuable tools for the development of rapid analytical 55 
methods enabling a more efficient control of chemical residues in 
foodsttufs and the environment. Since low molecular weight 
compounds like kresoxim-methyl are not able to trigger an 
immune response by themselfs (so-called haptens), 
immunochemical methods rely on the availability of appropriate 60 
bioconjugates. Prior to antibody production, a rational design of 
functionalized haptens for covalent coupling to carrier proteins 
has long been recognized to be a critical step for high-quality 
antibody generation and sensitive assay development.6-10 Hapten 
functionalization aims at synthesizing an analogue of the target 65 
compound which holds a spacer arm with a reactive or activatable 
chemical group at the free end of the linker. Thus, several criteria 
need to be considered before haptens are prepared, such as the 
functional moiety, the length and composition of the linker, and 
the derivatization site that will be most adequate for optimum 70 
immune response. For the functional group, carboxylates are 
mostly preferred because they can easily be protected and 
deprotected for chemical synthesis, and they can be readily 
activated for high-yield covalent coupling to the abundantly 
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available ε-amine groups of lysine residues in proteins. The 
importance of linker composition and length has been 
investigated by our group and others.11-19 Generally, linear 
aliphatic hydrocarbon chains are preferred due to their low 
immunogenicity, and medium-size spacers (four to six-carbon 5 
long) are mostly recommended for the generation of high-affinity 
and selective antibodies,20, 21 although other linker lengths and 
compositions have also been employed.22-26 Last but not least, the 
linker tethering site decides the ultimate orientation of the hapten, 
thus determining upon immunization the formation of the 10 
antibody binding site, and consequently influencing detectability 
and selectivity.27-34 
  
 
Fig. 1. A) Global minimum energy conformation of kresoxim-methyl. Calculations were performed using Molecular Mechanics (MM3) as implemented 15 
in the CAChe program. A systematic conformational search was performed (all rotatable bonds were rotated by 15 degree steps) and the geometry of the 
generated conformers was refined by performing an optimized geometry calculation in MOPAC using PM3 parameters. Arrows denote the spacer-arm 
attachment site in each of the haptens. B) Structure of kresoxim-methyl (KM), the synthesized haptens, and the corresponding N-succinimidyl esters 
(activated haptens). 
 20 
 
 Functionalized haptens for kresoxim-methyl were previously 
prepared by our group through derivatization at the carboxyl 
group of the (methoxyimino)acetate moiety, using as linkers 
dipeptides or linear aliphatic chains of different lengths.12 In the 25 
present study, a thorough approach has been undertaken in order 
to investigate the effect of the derivatization site on the 
generation of high-quality antibodies for this chemical. Five 
regioisomeric haptens – carrying identical spacers – were 
prepared with alternative rationally-chosen linker tethering sites, 30 
thus covering a wide variety of spatial orientations of the target 
molecule. A comprehensive study was undertaken so as to clarify 
the influence of hapten orientation over the immune system 
response. Rabbit polyclonal antibodies (pAb) and mouse 
monoclonal antibodies (mAb) were generated in order to evaluate 35 
the antibody-eliciting capability of the different haptens. 
Antibody apparent affinity was first estimated using homologous 
enzyme-linked immunosorbent assay (ELISA), and finally the 
influence of tethering-site heterology was assessed for each 
antibody/hapten combination. 40 
Results and discussion 
Hapten syntheses 
The kresoxim-methyl framework exhibited significant 
conformational flexibility due to the large number of bonds 
displaying free rotation. Calculations showed that, like natural 45 
strobilurins and several of its synthetic analogues,35 kresoxim-
methyl does not adopt an extended geometry, so all minimum-
energy conformations are characterized by the nearly orthogonal 
disposition of the two planar phenyl moieties (see Fig. 1A for the 
most stable conformation). Particularly relevant is the high 50 
degree of conformational flexibility of the (methoxyimino)acetate 
moiety, which can adopt several energetically equivalent 
orientations by rotation around the C–C bond that connects it to 
the aromatic backbone. On the basis of the above conformational 
analysis, five different positions of the kresoxim-methyl 55 
framework were selected for incorporation of the linker, trying to 
cover as many spatial orientations of the target molecule as 
possible (Fig. 1A and 1B). All of the designed hapten structures 
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maintained the complete hydrocarbon skeleton and functional 
groups of the target analyte, incorporating the same aliphatic 
spacer arm at positions where minimum modifications of 
electronic, steric, and conformational features of the molecule 
were expected. 5 
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Fig. 2. Synthetic sequence for the preparation of haptens KMa, KMb, and KMc. 
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 The synthesis of the haptens started from kresoxim-methyl 
itself (haptens KMb and KMe) or from an aryl system that 
already incorporated the (E)-2-(methoxyimino)acetate moiety 
(haptens KMa, KMc, and KMo). In all cases, the alkyl C-6 
carboxylated spacer arm was introduced in the form of tert-butyl 5 
ester, either through a Sonogashira cross-coupling reaction with 
the appropriate alkyne or by means of an O-alkylation reaction 
with the corresponding tert-butyl alkyl-bromoester. For all of the 
haptens, the synthesis was completed by acid hydrolysis of the 
tert-butyl ester moiety. 10 
  
 
Fig. 3. Synthetic sequences for the preparation of haptens KMe and KMo.  
 15 
 As it is shown in Fig. 2, the syntheses of haptens KMa, KMb, 
and KMc followed a common strategy based on the initial 
preparation of an iodinated derivative of kresoxim-methyl. The 
rest of the steps to complete the synthesis of these haptens from 
the key iodinated intermediate (3, 7, or 12) implied 20 
palladium/cooper catalyzed Sonogashira cross-coupling reaction 
with the terminal triple bond of tert-butyl hex-5-ynoate (4) (to 
give aryl-alkynes 5, 8, or 13), followed by hydrogenation of the 
triple bond under homogeneous conditions using Wilkinson's 
catalyst (to afford 6, 9, or 14), and finally, acidic hydrolysis of the 25 
tert-butyl ester group to provide haptens KMa, KMb, and KMc in 
61%, 73%, and 55% overall yield, respectively, from the 
corresponding starting material. 
 
 The synthesis of hapten KMe was readily accomplished in 30 
three steps (Fig. 3, left-hand side); i.e., alkaline hydrolysis of 
methyl ester group of kresoxim-methyl to give carboxylic acid 
15, followed by O-alkylation of the carboxylate group with 
tert-butyl 6-bromohexanoate (16), and acid hydrolysis of the 
tert-butyl ester group. This straightforward sequence afforded 35 
hapten KMe in nearly 60% overall yield from the starting 
material. 
 Finally, for the synthesis of hapten KMo we made use of 
benzyl-bromide 19 (Fig. 3, right-hand side), prepared in high 
yield from oxime 18 in two successive steps, first O-alkylation of 40 
the oxime moiety with tert-butyl 6-bromohexanoate (16) 
followed by radical bromination of the benzylic position with 
NBS. The synthesis of hapten KMo was completed from 19 via 
C-alkylation reaction of the benzylic position with o-cresol 
followed by formic acid promoted hydrolysis of the tert-butyl 45 
ester group. The overall yield of the synthesis of hapten KMo 
from starting material 18 was about 68%. 
Protein conjugate preparation 
Bioconjugates to BSA, OVA, and HRP were prepared with each 
synthetic hapten using N,N’-disucciminidyl carbonate as 50 
activating reagent. With this strategy, the active ester (NHS ester, 
see Fig. 1) of the hapten could be easily purified. Since pure 
activated haptens were employed for coupling, no unwanted 
secondary reactions occurred during conjugation; thus, the same 
chemical strategy could be followed both for immunogen and for 55 
assay antigen preparation. Immunizing conjugates showed 
hapten-to-protein molar ratios between 13 and 16, whereas molar 
ratios for OVA and HRP conjugates were between 3 and 5; 
meaning that around half of the available lysine ε-amine groups 
of BSA, one fourth of OVA, and all those of HRP most likely 60 
held hapten molecules. 
Immune response and polyclonal antibody characterization 
Two pAbs were generated from each immunogen, which were 
named after the immunizing hapten, and numbered. Every 
immunogen (BSA conjugates) was able to elicit a satisfactory 65 
immune response, with titers higher than 1/10000 as determined 
by direct ELISA. Evaluation of the affinity of antibodies raised 
by the different haptens was done by comparison of the IC50 
values from assays with homologous conjugates, i.e., those 
carrying the same hapten than the immunogen but coupled to 70 
HRP. The affinities of each pair of antisera that was generated 
from the same immunizing hapten were essentially equivalent 
(Table 1), perhaps with the only exception of the two pAbs 
produced from hapten KMa (rKMa#1 and rKMa#2), whose IC50 
values differed 4-fold. The highest affinity to kresoxim-methyl 75 
was found with KMo-type antibodies (obtained from hapten 
KMo), followed by those triggered by hapten KMe. Contrarily, 
antibodies with higher IC50 values were produced from haptens 
containing the spacer arm at the b-ring (haptens KMb and KMc) 
or at the a-ring (hapten KMa). Among these three haptens, 80 
probably the most surprising and unexpected result was the poor 
performance of KMb-type antibodies because the position of the 
linker in hapten KMb should not theoretically cause steric 
hindrance, and minimum electronic or conformational 
modifications were involved. 85 
 This journal is © The Royal Society of Chemistry [year] Journal Name, [year], [vol], 00–00  |  5 
Table 1 IC50 (nM) values for kresoxim-methyl from assays using 
polyclonal antibodies.a 
 Enzyme tracer 
pAb KMa KMb KMc KMe KMo 
rKMa#1 28 –b – – 5 
rKMa#2 117 – – – 25 
rKMb#1 – 350 36 16 13 
rKMb#2 – 300 19 9 – 
rKMc#1 268 30 180 2 – 
rKMc#2 76 1000 200 – – 
rKMe#1 23 12 4 11 5 
rKMe#2 48 20 9 27  – 
rKMo#1 – – – 4 3 
rKMo#2 4 5 – 3 7 
a Values are the mean of three independent experiments. Homologous 
combinations are indicated in bold-type letter. b Amax was lower than 0.8 
at the highest tested tracer concentration (300 ng mL-1 ) and at the 
lowest assayed antiserum dilution (1/3000). 
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Fig. 4. Inhibition curves for the best pAb from each immunizing hapten 
as evaluated by homologous competitive ELISA. Values are the mean of 
three independent experiments. 5 
Fig. 5. Standard inhibition curves for antibody rKMc#1 using the HRP–
KMc homologous tracer (▲) and the HRP–KMe heterologous tracer (■). 
Values are the mean of three independent experiments. 
 The differences in kresoxim-methyl recognition exhibited by 
the produced pAbs as a function of the hapten derivatization site 10 
can be observed in Fig. 4. In previous studies with other 
strobilurins, functionalization through the toxophore moiety, 
particularly at the methoxy group, also resulted in optimum 
affinity responses.36-38 With the linker at such position, the 
characteristic aromatic rings of the molecule seem to be better 15 
exposed to the immune system. In contrast, the a-ring was 
revealed as a less adequate site for derivatization – particularly in 
para position from the (methoxyimino)acetate group – if high-
affinity antibodies are sought. 
 It is well-known, particularly with pAbs, that changes in 20 
hapten structure can decrease the recognition towards the 
corresponding assay conjugate, thus enhancing the interaction of 
the antibody with the target molecule and therefore increasing the 
apparent affinity.9, 24, 25, 29, 30, 39, 40 Accordingly, kresoxim-methyl 
binding by the different antisera was tested with heterologous 25 
HRP conjugates (Table 1). The number of working combinations 
of immunoreagents was higher than expected, taking into account 
that linkers had been introduced at very different positions of the 
molecular framework in the immunizing and in the assay hapten. 
KMe-type antibodies were able to perfectly tolerate site-30 
heterologies, whereas KMa-type antibodies just recognized the 
HRP–KMo heterologous tracer. 
 On the other hand, if adequate binding to the conjugate 
occurred, most heterologous combinations helped to considerably 
improve the antibody apparent affinity, mostly for those pAbs 35 
that had rendered high IC50 values with the homologous 
conjugate. In fact, pAb rKMc#1 improved the IC50 value 90-fold 
with the conjugate HRP–KMe (Fig. 5), and pAb rKMb#2 
increased its apparent affinity 30-fold also with HRP–KMe. 
Nevertheless, most combinations with IC50 values in the low 40 
nanomolar range still were obtained with antibodies raised by the 
best immunizing haptens, KMo and KMe. 
Monoclonal antibody characterization 
In order to generate high-affinity kresoxim-methyl binders, 
hybridomas were selected following a double screening 45 
competitive procedure. By this strategy, a collection of novel 
mAbs coming from mice immunized with each of the synthesized 
haptens was attained. Each antibody was named after the 
immunizing hapten, and numbered. All of the antibodies were 
comprised by κ light chains and were of the IgG1 isotype, except 50 
mAbs KMa#26 and KMb#322 which were of the IgG2b isotype. 
 Affinity-purified mAbs were characterized versus the 
homologous and all of the site-heterologous conjugates by 
checkerboard competitive direct ELISA. Half of the mAbs did 
not work satisfactorily, not even with the homologous enzyme 55 
tracer (Table 2). Such behavior upon mAb immobilization has 
been previously observed by several authors, and it is commonly 
ascribed to conformational changes of antibodies resulting from 
direct adsorption to hydrophobic surfaces.41-44 As a foremost 
result, working mAbs exhibited IC50 values below 2 nM. 60 
Interestingly, HRP conjugates of haptens KMe and KMo – 
holding the linker at the (methoxyimino)acetate moiety – were 
bound by both KMe- and KMo-type antibodies, indicating a 
certain equivalency of these two adjacent derivatization sites. It is 
worthy to note that high-affinity mAbs were obtained from 65 
hapten KMb. This result contrasts with the poor affinity exhibited 
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A/
A 0
  x
 1
00
0
20
40
60
80
100
 6  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
by KMb-type pAbs, and raises the question of whether 
information from rabbit antisera is a useful criterion in order to 
select optimum haptens for hybridoma technology. In addition, 
antibody KMb#322 recognized all four heterologous tracers, yet 
similar IC50 values were derived from all reagent combinations. 5 
  
Table 2  IC50 values (nM) for kresoxim-methyl from assays using 
monoclonal antibodies.a 
 Enzyme tracer 
mAb KMa KMb KMc KMe KMo 
KMa#26 – b – – – – 
KMa#29 – – – – – 
KMb#19 – – – – – 
KMb#32 – 2.02 0.60 0.68 – 
KMb#44 – 3.41 – – – 
KMb#322 0.60 0.76 0.66 0.97 0.78 
KMc#35 – – – – – 
KMe#14 – – – 1.77 1.72 
KMe#18 – – – 1.90 1.05 
KMe#26 – – – – – 
KMe#211 – – – – – 
KMo#111 – – – 2.13 2.08 
KMo#114 – – – – – 
KMo#117 – – – 1.97 1.70 
a Values are the mean of three independent determinations and 
correspond to an inhibition curve with an Amax value between 0.8 and 
1.5. Antibody concentration was either 300 or 1000 ng mL−1. b Amax 
values were lower than 0.8 at 300 ng mL−1 tracer concentration and 
the highest coating concentration (mAb at 1 µg mL−1). 
 
 
 To gain further insights into the kresoxim-methyl binding 
properties of the mAb collection, binders were also examined in 10 
solution by competitive ELISA with immobilized OVA–hapten 
conjugates. As shown in Table S1, general remarks were 
essentially identical; haptens KMo, KMe and KMb were 
confirmed as the best mimics in order to generate high-affinity 
anti-kresoxim-methyl mAbs, whereas haptens KMa and KMc just 15 
elicited antibodies of moderate affinity. Moreover, the widest 
tolerance to site-heterologies was again observed with mAbs that 
had been triggered from hapten KMb. 
Conclusions 
A differential response of the immune system to a battery of 20 
kresoxim-methyl regioisomeric haptens with the linker at a 
variety of sites was observed, thus proving a relationship between 
the structure of the immunizing hapten and the apparent affinity 
of derived antibodies. It was seen that derivatization at the a-ring 
of strobilurins triggered a moderate immune response in terms of 25 
affinity to kresoxim-methyl, as observed before for other 
compounds of this family. On the contrary, high-affinity 
polyclonal and monoclonal antibodies were obtained from 
immunogens with the linker at either end of the 
(methoxyimino)acetate moiety, which possess higher 30 
conformational freedom. Results from a hapten carrying the 
linker at the para position of the characteristic o-cresol ring 
(hapten KMb) strongly differed between rabbit pAbs and mouse 
mAbs. Despite of the drastic alteration introduced by site-
heterologies, pAbs are complex enough to be able to bind such 35 
conjugates and to permit considerable sensitivity improvements, 
mainly with moderate-affinity antibodies. On the contrary, few 
mAbs could tolerate such severe changes in hapten structure, 
especially if the assay hapten held the linker at an opposite site 
with respect to the immunizing hapten.  40 
Experimental 
Chemicals and general procedures 
tert-Butyl hex-5-ynoate and tert-butyl 6-bromohexanoate were 
prepared by esterification with isobutene of commercial hex-5-
ynoic acid and 6-bromohexanoic acid, respectively, following a 45 
previously described procedure for the preparation of related tert-
butyl esters.15 Other chemical reagents were purchased from 
regular sources and used without purification. All operations 
involving air-sensitive reagents were performed under an inert 
atmosphere of dry nitrogen or argon using syringe and cannula 50 
techniques, oven-dried glassware, and freshly distilled and dried 
solvents. Organic solvents were dried and distilled before use 
according to standard procedures.45 Reactions were followed by 
thin-layer chromatography using 0.25 mm pre-coated silica gel 
plates and products were visualized by UV light (254 nm) and 55 
aqueous ceric ammonium molybdate solution or 50% (v/v) 
concentrated H2SO4 in water and then heating with a high-
temperature air dryer. Unless otherwise stated, reaction mixtures 
were worked up by addition of water, and extraction with the 
appropriate solvent, the organic layer being washed with water 60 
and/or brine and dried using anhydrous magnesium or sodium 
sulfate. Evaporation of the solvent was performed under reduced 
pressure using a rotary evaporator. Synthesized compounds were 
purified by flash chromatography with a silica gel column (Merck 
60, 230–400 mesh). Melting points and spectra were recorded as 65 
in previous studies [8].38 The most stable conformation of 
kresoxim-methyl was calculated with CAChe WorkSystem Pro 
software, version 7.5.0.85 (Fujitsu Ltd, Tokyo, Japan). 
 Kresoxim-methyl (methyl (E)-methoxyimino[α-(o-tolyloxy)-o-
tolyl]acetate, CAS Registry No. 143390-89-0, MW 313.35 g 70 
mol−1), Pestanal grade, was purchased from Fluka/Riedel-de-
Haën (Seelze, Germany). Horseradish peroxidase (HRP), 
ovalbumin (OVA), N,N'-disuccinimidyl carbonate (DSC), 
Freund’s adjuvants, and o-phenylenediamine were purchased 
from Sigma/Aldrich (Madrid, Spain). Rabbit anti-mouse 75 
immunoglobulins polyclonal antibody–peroxidase conjugate 
(RAM–HRP) was from Dako (Glostrup, Denmark). Bovine 
serum albumin (BSA) fraction V and Hybridoma Fusion and 
Cloning Supplement (HFCS) were obtained from Roche Applied 
Science (Mannheim, Germany). P3-X63-Ag8.653 mouse 80 
plasmacytoma cell line was acquired from the European 
Collection of Cell Cultures (Wiltshire, UK). Polyethylene glycol 
Hybri-Max (PEG 1500), cell culture media (high-glucose 
Dulbecco’s Modified Eagle’s Medium, DMEM), non-essential 
amino acid solution, 200 mM alanyl-glutamine solution, fetal 85 
bovine serum (FBS), and red blood cell lysing buffer were bought 
to Sigma/Aldrich (Madrid, Spain). Gentamicine, hipoxanthine–
aminopterine–thimidine (HAT), and hipoxanthine–thimidine 
(HT) solutions were obtained from Gibco BRL (Paisley, 
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Scotland). Culture plastic ware and Costar 96-well flat-bottom 
high-binding polystyrene ELISA plates were from Corning 
(Corning, NY, USA). Sephadex G-25 HiTrap Desalting columns 
and Sepharose HiTrap Protein G HP columns from GE-
Healthcare (Uppsala, Sweden) were used for conjugate and for 5 
antibody purification, respectively, in the ÄKTA workstation. 
Ultraviolet–visible spectra and ELISA absorbances were read 
with a PowerWave HT from BioTek Instruments (Winooski, VT, 
USA). Microwells were washed with an ELx405 microplate 
washer also from BioTek Instruments. The immunoglobulin 10 
isotype was determined using the Mouse MonoAb-ID kit from 
Invitrogen (Carlsbad, CA, USA).  
 Composition, concentration, and pH of the employed buffers 
and solutions were as follows: i) CB, 50 mM sodium carbonate–
bicarbonate buffer, pH 9.6; ii) PB, 100 mM sodium phosphate 15 
buffer, pH 7.4; iii) PBS, 10 mM sodium phosphate buffer, pH 
7.4, with 140 mM NaCl; iv) PBST, PBS containing 0.05% (v/v) 
Tween 20; v) washing solution, 150 mM NaCl containing 0.05% 
(v/v) Tween 20; and vi) substrate solution, 0.012% (v/v) H2O2 
and 2 mg mL−1 o-phenylenediamine in 25 mM sodium citrate and 20 
62 mM sodium phosphate buffer, pH 5.4. 
Syntheses of haptens 
Five functionalized regioisomeric haptens of kresoxim-methyl 
with a C-6 hydrocarbon spacer arm located at selected sites of the 
molecular skeleton were synthesized (Fig. 1). Experimental 25 
details of their preparation are given below, while a detailed 
description of full spectroscopic data of all synthetic 
intermediates is provided in the Supplementary Data file (Fig. S1 
to S5). 
Synthesis of hapten KMa (Fig. 2) 30 
Synthesis of (E)-methyl 2-(4-iodo-2-((o-tolyloxy)methyl)phenyl)-
2-(methoxyimino)acetate (3).  
A mixture of benzyl bromide 1 (112 mg, 0.272 mmol), prepared 
in three steps from 1-iodo-3-methylbenzene (see the 
Supplementary Data file), o-cresol (2, 28 µL, 0.272 mmol), and 35 
anhydrous Cs2CO3 (133 mg, 0.408 mmol) in dry 
N,N-dimethylformamide (DMF) (1.3 mL) was stirred under 
nitrogen for 6 h, poured into water, and worked up using EtOAc. 
Chromatography of the residue left after evaporation of the 
solvent, using hexane–Et2O (from 9:1 to 8:2) as eluent, afforded 40 
benzyl ether 3 (107.5 mg, 90%) as an oil. 
Synthesis of (E)-tert-butyl 6-(4-(2-methoxy-1-(methoxyimino)-2-
oxoethyl)-3-((o-tolyloxy)methyl) phenyl)hex-5-ynoate (5). 
A solution of tert-butyl hex-5-ynoate (4, 155 mg, 0.920 mmol) in 
anhydrous degassed DMF (1.0 mL) was added to a mixture of 45 
aryl iodide 3 (101 mg, 0.230 mmol), CuI (1.3 mg, 0,007 mmol, 
3% mol) and (Ph3P)2PdCl2 (4.8 mg, 0.007 mmol, 3% mol) under 
nitrogen atmosphere. After the addition anhydrous Et3N (0.5 
mL), the reaction mixture, initially yellow that turned deep-red 
after a few minutes, was stirred at room temperature for 6 h, then 50 
poured into water, and worked up in the usual manner using 
EtOAc to extract. Work up as usual and chromatography of the 
crude product with hexane–Et2O (7:3) as eluent afforded alkyne 5 
(94.7 mg, 86%) as a colorless oil.  
Synthesis of (E)-tert-butyl 6-(4-(2-methoxy-1-(methoxyimino)-2-55 
oxoethyl)-3-((o-tolyloxy)methyl) phenyl) hexanoate (6). 
A mixture of alkyne 5 (56.3 mg, 0.117) and Rh(PPh3)3Cl (3.3 mg, 
0.003 mmol) in anhydrous tetrahydrofuran (THF; 1 mL) was 
stirred under an atmosphere of hydrogen at 4 atm during 16 h. 
The reaction mixture was concentrated to dryness and the 60 
obtained residue was purified by chromatography, using hexane–
EtOAc (9:1) as eluent, to give the title compound 6 (48.2 mg, 
85%) as a brownish oil.  
Synthesis of (E)-6-(4-(2-methoxy-1-(methoxyimino)-2-oxoethyl)-
3-((o-tolyloxy)methyl)phenyl) hexanoic acid (hapten KMa). 65 
A solution of tert-butyl ester 6 (48.2 mg, 0.099 mmol) in formic 
acid (2 mL) was stirred at room temperature under nitrogen for 3 
h. Then, the reaction mixture was diluted with benzene and 
washed with cold water until pH 6–7, and dried over anhydrous 
Na2SO4. Chromatographic purification of the residue left after 70 
evaporation of the solvent, using CHCl3 as eluent, afforded 
hapten KMa (39.3 mg, 93%) as colorless oil.  
Synthesis of hapten KMb (Fig. 2) 
Synthesis of (E)-methyl 2-(2-((4-iodo-2-
methylphenoxy)methyl)phenyl)-2-(methoxyimino)acetate (7). 75 
A 1.53 M solution of ICl in CH2Cl2 (4.5 mL, 6.885 mmol) was 
added drop wise to a solution of kresoxim-methyl (537.5 mg, 
1.720 mmol) in AcOH (3 mL) at room temperature. The resulting 
mixture was stirred during 5 h, then poured into water and 
extracted with EtOAc. The combined organic layers were washed 80 
successively with a 10% aqueous solution of sodium thiosulfate, 
water and brine, dried over anhydrous Na2SO4 and concentrated, 
and the obtained residue was purified by chromatography, using 
hexane–EtOAc (8:2) as eluent, to give the aryl iodide 7 (718.4 
mg, 95%) as a white solid. Mp. 124–125 °C (crystallized from 85 
hexane–benzene). 
Synthesis of (E)-tert-butyl 6-(4-((2-(2-methoxy-1-(methoxyimino)-
2-oxoethyl)benzyl)oxy)-3-methylphenyl) hex-5-ynoate (8). 
The synthesis of this compound was performed following the 
same procedure reported for compound 5, starting from aryl 90 
iodide 7 (529.8 mg, 1.21 mmol), alkyne 4 (811 mg, 4.84 mmol), 
CuI (6.9 mg, 0.040 mmol), Pd(PPh3)2Cl2 (25.5 mg, 0.040 mmol), 
DMF (3.9 mL), and Et3N (2.9 mL), and 3 h of reaction time. The 
crude product was purified by chromatography, using hexane–
EtOAc (from 9:1 to 8:2) as eluent, to give alkyne 8 (545.8 mg, 95 
95%) as a yellowish oil.  
Synthesis of (E)-tert-butyl 6-(4-((2-(2-methoxy-1-(methoxyimino)-
2-oxoethyl)benzyl)oxy)-3-methylphenyl)hexanoate (9). 
Alkyne 8 (499.4 mg, 1.041 mmol) was hydrogenated as described 
above for the preparation of 6 using Rh(PPh3)3Cl (28.9 mg, 0.031 100 
mmol) and THF (9.5 mL). Purification of the crude product by 
chromatography with hexane–EtOAc (8:2) as eluent gave title 
compound 9 (455.8 mg, 90%) as a semisolid.  
Synthesis of (E)-6-(4-((2-(2-methoxy-1-(methoxyimino)-2-
oxoethyl)benzyl)oxy)-3-methylphenyl) hexanoic acid (hapten 105 
KMb). 
Hydrolysis of the tert-butyl ester moiety of 9 (159 mg, 
0.329 mmol) with formic acid (6.8 mL) under the same 
conditions reported above for 6, followed by purification by 
chromatography using CHCl3 as eluent, afforded hapten KMb 110 
(127.8 mg, 91%) as a slightly colored oil.  
Synthesis of hapten KMc (Fig. 2) 
Synthesis of (E)-methyl 2-(2-((2-iodophenoxy)methyl)phenyl)-2-
(methoxyimino)acetate (12). 
This compound was prepared basically according to the 115 
procedure already described for compound 6 starting from benzyl 
bromide 10 (74.2 mg, 0.259 mmol),46 2-iodophenol (11, 30 µL, 
0.259 mmol), and Cs2CO3 (125 mg, 0.388 mmol) in DMF (1.5 
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mL), and 4 h of reaction time. The crude product was purified by 
chromatography, using hexane–Et2O (7:3) as eluent, to give title 
compound 12 (72.6 mg, 90%) as a white solid. Mp. 87–89 °C 
(crystallized from hexane–benzene). 
Synthesis of (E)-tert-butyl 6-(2-((2-(2-methoxy-1-(methoxyimino)-5 
2-oxoethyl)benzyl)oxy)phenyl) hex-5-ynoate (13). 
The synthesis of this compound was performed following the 
same procedure that was described above for compound 5, 
starting from aryl iodide 12 (78.0 mg, 0.239 mmol), alkyne 4 
(48.0 mg, 0.287 mmol), CuI (1.4 mg, 0.007 mmol), Pd(PPh3)2Cl2 10 
(5.0 mg, 0.007 mmol), DMF (1.0 mL), and Et3N (0.5 mL), and 2 
h of reaction time. The crude product was purified by 
chromatography, using hexane–Et2O (8:2) as eluent, to give 13 
(65.6 mg, 75%) as a colorless oil. 
Synthesis of (E)-tert-butyl 6-(2-((2-(2-methoxy-1-(methoxyimino)-15 
2-oxoethyl)benzyl)oxy)phenyl) hexanoate (14). 
Alkyne 13 (65.6 mg, 0.180 mmol) was hydrogenated as described 
above for the preparation of 6 using Rh(PPh3)3Cl (5.0 mg, 0.005 
mmol) and THF (1.6 mL). Purification of the crude product by 
chromatography with hexane–Et2O (from 9:1 to 8:2) as eluent 20 
gave title compound 14 (60.8 mg, 91 %) as a colorless oil. 
Synthesis of (E)-6-(2-((2-(2-methoxy-1-(methoxyimino)-2-
oxoethyl)benzyl)oxy)phenyl)hexanoic acid (hapten KMc). 
Hydrolysis of the tert-butyl ester group of 14 (60.8 mg, 0.165 
mmol) with formic acid (3.4 mL) under the same conditions 25 
reported above for 6 afforded, after chromatographic purification 
with CHCl3 as eluent, hapten KMc (46.5 mg, 90%) as a white 
solid. Mp. 86–89 °C (crystallized from hexane).  
Synthesis of hapten KMe (Fig. 3) 
Synthesis of (E)-tert-butyl 6-(2-(methoxyimino)-2-(2-((o-30 
tolyloxy)methyl)phenyl)acetoxy) hexanoate (17). 
tert-Butyl 6-bromohexanoate (16, 100.6 mg, 0.401 mmol) was 
added to a mixture of acid 15 (100 mg, 0.334 mmol), obtained by 
basic hydrolysis of the methyl ester moiety of kresoxim-methyl 
following the procedure previously described,12 and anhydrous 35 
K2CO3 (54.4 mg, 0.401 mmol) in dry DMF (13 mL) under 
nitrogen at room temperature. The resulting mixture was stirred 
for 24 h, then poured into water, and worked up in the usual 
manner extracting with EtOAc. Purification of the crude product 
by chromatography, using hexane–Et2O (from 8:2 to 7:3) as 40 
eluent, afforded title compound 17 (110 mg, 70%) as a colorless 
oil 
Synthesis of (E)-6-(2-(methoxyimino)-2-(2-((o-
tolyloxy)methyl)phenyl)acetoxy)hexanoic acid (hapten KMe). 
Hydrolysis of the tert-butyl ester group of 17 (36.9 mg, 0.078 45 
mmol) with formic acid (1.6 mL) under the same conditions 
reported above for 6 afforded, after chromatographic purification 
with CHCl3 as eluent, hapten KMe (30.6 mg, 93%) as a colorless 
oil.  
Synthesis of hapten KMo (Fig. 3) 50 
Preparation of (E)-tert-butyl 6-(((1-(2-(bromomethyl)phenyl)-2-
methoxy-2-oxoethylidene)amino) oxy)hexanoate (19). 
A mixture of oxime 18 (synthesized following the procedure 
described by Li et al.)47, 48 (90 mg, 0.466 mmol), tert-butyl 6-
bromohexanoate (16, 117 mg, 0.466 mmol), and anhydrous 55 
Cs2CO3 (228 mg, 0.699 mmol) in dry DMF (1.7 mL) was stirred 
under nitrogen for 4 h, poured into water, and worked up as usual 
using EtOAc to extract. Chromatography of the crude product, 
using hexane–EtOAc (9:1) as eluent, afforded the corresponding 
intermediate O-alkylated oxime (141 mg, 83%) as a colorless oil. 60 
A solution of the above obtained oxime (123 mg, 0.339 mmol), 
NBS (60.3 mg, 0.339 mmol), and AIBN (3.3 mg, 0.020 mmol) in 
anhydrous benzene (1.5 mL) was degassed by nitrogen bubbling 
and ultrasound for 15 min and then heated at reflux overnight. 
The reaction mixture was allowed to cool at room temperature, 65 
diluted with EtOAc, and worked up as usual to afford the crude 
product as a pale brown oil. Purification by column 
chromatography, using hexane–Et2O (from 9:1 to 8:2) as eluent, 
gave benzyl bromide 19 (137.8 mg, 92%; 76% overall yield from 
18) as a brownish oil.  70 
Synthesis of (E)-tert-butyl 6-(((2-methoxy-2-oxo-1-(2-((o-
tolyloxy)methyl)phenyl)ethylidene) amino)oxy)hexanoate (20). 
This compound was prepared following the procedure described 
above for compound 3 but starting from benzyl bromide 19 (54.7 
mg, 0.124 mmol), o-cresol (12.8 µL, 0.124 mmol), and Cs2CO3 75 
(60.6 mg, 0.186 mmol) in DMF (522 µL). The crude product was 
purified by chromatography, using hexane–Et2O (9:12) as eluent, 
to give title compound as a colorless oil (57.6 mg, 99%). 
Synthesis of (E)-6-(((2-methoxy-2-oxo-1-(2-((o-
tolyloxy)methyl)phenyl)ethylidene)amino)oxy) hexanoic acid 80 
(hapten KMo). 
Hydrolysis of the tert-butyl ester moiety of 20 (115.2 mg, 0.246 
mmol) with formic acid (5.0 mL) was carried out under the same 
conditions reported above for 6, and after chromatographic 
purification with CHCl3 as eluent, hapten KMo (91.4 mg, 90%) 85 
was obtained as a colorless oil.  
Preparation of hapten active esters 
The synthesized haptens were activated by formation of the 
corresponding N-hydroxysuccinimidyl ester (NHS ester) using 
DSC. Anhydrous Et3N (54 μL, 0.38 mmol, 3.8 equiv) was added 90 
to a solution of the hapten (0.1 mmol) and DSC (26 mg, 0.13 
mmol, 1.3 equiv) in dry acetonitrile (1 mL) under nitrogen at 0 
°C. The reaction mixture was stirred at room temperature 
overnight, then diluted with CHCl3, washed with a 10% aqueous 
solution of NaHCO3 and brine, and dried over anhydrous 95 
Na2SO4. Chromatographic purification of the residue that was left 
after evaporation of the solvent, using CHCl3 as eluent, afforded 
the NHS esters in good yield (70–99%) and high purity, as shown 
by 1H NMR spectroscopy (copies of original spectra are included 
in the Supplementary Data file). 100 
KMa-NHS ester: (88% yield). 1H NMR (CDCl3, 300 MHz)  
7.37 (1H, br s, H-2’), 7.20 (1H, dd, J = 7.8, 1.5 Hz, H-6’), 7.14–
7-07 (3H, m, H-5’, H-3’’ and H-5’’), 6.85 (1H, br dd, J = 7.5, 7.5 
Hz, H-4’’), 6.78 (1H, br d, J = 8.1 Hz, H-6’’), 4.93 (2H, s, 
OCH2), 4.02 (3H, s, NOCH3), 3.81 (3H, s, CO2CH3), 2.82 (4H, br 105 
s, OCCH2CH2CO), 2.67 (2H, t, J = 7.5 Hz, H-6), 2.59 (2H, t, J = 
7.5 Hz, H-2), 2.24 (3H, s, CH3), 1.78 and 1.69 (2H each, two 
partially overlapped quint, J = 7.5 Hz, H-5 and H-3), 1.45 (2H, 
m, H-4). 
KMb-NHS ester: (70% yield). 1H NMR (C6D6, 300 MHz) 7.45 110 
(1H, dd, J = 7.4, 1.3 Hz, H-3’’), 7.16 (1H, signal hidden by 
solvent peak, H-6’’), 7.08 (1H, ddd, J = 7.4, 7.4, 1.7 Hz, H-4’’), 
7.02 (1H, ddd, J = 7.4, 7.4, 1.3 Hz, H-5’’), 6.89 (1H, br s, H-2’), 
6.83 (1H, dd, J = 8.3, 1.9 Hz, H-6’), 6.72 (1H, d, J = 8.3 Hz, 
H-5’), 5.02 (2H, s, OCH2), 3.61 (3H, s, NOCH3), 3.36 (3H, s, 115 
CO2CH3), 2,37 (5H, s and t overlapped, CH3 and H-6), 2.11 (2H, 
t, J = 7.4 Hz, H-2), 1.7–1.5 (4H, m, OCCH2CH2CO), 1.5–1.3 
(4H, two partially overlapped quint, J = 7.7 Hz, H-5 and H-3), 
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1.12 (2H, m, H-4). 
KMc-NHS ester: (98% yield). 1H NMR (CDCl3, 300 MHz)  
7.58 (1H, dd, J = 7.6, 1.5 Hz, H-3’’), 7.45 (1H, ddd, J = 7.6, 7.6, 
1.5 Hz, H-4’’), 7.38 (1H, ddd, J = 7.6, 7.6, 1.5 Hz, H-5’’), 7.19 
(1H, dd, J = 7.6, 1.5 Hz, H-6’’), 6.88 (1H, ddd, J = 7.5, 7.5, 1.2 5 
Hz, H-5’), 6.77 (1H, d, J = 8.1 Hz, H-3’), 4.95 (2H, s, OCH2), 
4.04 (3H, s, NOCH3), 3.84 (3H, s, CO2CH3), 2.83 (4H, br s, 
OCCH2CH2CO), 2.66 (2H, t, J = 7.5 Hz, H-6), 2.57 (2H, t, J = 
7.5 Hz, H-2), 1.77 (2H, quint, J = 7.5 Hz, H-5), 1.64 (2H, quint, J 
= 7.5 Hz, H-3), 1.47 (2H, m, H-4). 10 
KMe-NHS ester: (98% yield). 1H NMR (CDCl3, 300 MHz)  
7.57 (1H, br d, J = 7.5 Hz, H-6’), 7.44 (1H, ddd, J = 7.5, 7.5, 1.5 
Hz, H-5’), 7.38 (1H, ddd, J = 7.5, 7.5, 1.4 Hz, H-4’), 7.21 (1H, 
dd, J = 7.5, 1.5 Hz, H-3’), 7.15–1.07 (2H, m, H-3’’ and H-5’’), 
6.86 (1H, ddd, J = 7.5, 7.5, 1.0 HZ, H-4’’), 6.77 (1H, br d, J = 8.0 15 
Hz, H-6’’), 4.95 (2H, s, OCH2), 4.21 (2H, t, J = 6.8 Hz, H-6), 
4.03 (3H, s, NOCH3), 2.81 (4H, br s, OCCH2CH2CO), 2.52 (2H, 
t, J = 7.5 Hz, H-2), 2.25 (3H, s, CH3), 1.66 (4H, m, H-3 and H-5), 
1.37 (2H, m, H-4). 
KMo-NHS ester: (98% yield). 1H NMR (CDCl3, 300 MHz)  20 
7.57 (1H, br d, J = 7.5 Hz, H-6’), 7.44 (1H, ddd, J = 7.5, 7.5, 1.5 
Hz, H-5’), 7.38 (1H, ddd, J = 7.5, 7.5, 1.5 Hz, H-4’), 7.19 (1H, 
dd, J = 7.5, 1.2 Hz, H-3’), 7.11 (2H, m, H-3’’ and H-5’’), 6.85 
(1H, ddd, J = 7.2, 7.2, 0.9 HZ, H-4’’), 6.76 (1H, br d, J = 7.8 Hz, 
H-6’’), 4.95 (2H, s, OCH2), 4.24 (2H, t, J = 6.9 Hz, H-6), 3.81 25 
(3H, s, CO2CH3), 2.81 (4H, br s, COCH2CH2CO), 2.50 (2H, t, J = 
7.5 Hz, H-2), 2.24 (3H,s, CH3), 1.66 (4H, two overlapped quint, J 
= 7.8 Hz, H-3 and H-5), 1.37 (2H, m, H-4). 
Preparation of bioconjugates 
For immunogen preparation, 100 µL of a 50 mM purified 30 
activated hapten (NHS ester) solution in DMF was added to a 1 
mL BSA solution (15 mg mL−1) in CB. OVA conjugates were 
prepared by addition of 100 µL of a 30 mM purified activated 
hapten solution in DMF over 2 mL of protein solution (15 mg 
mL−1) in CB. Likewise, enzyme tracers were prepared by adding 35 
100 µL of a 10 mM purified hapten-NHS ester solution in DMF 
over a 1 mL HRP solution (2.2 mg mL−1) in CB. Mixtures were 
incubated 4 h at room temperature in amber glass vials and 
conjugates were purified by size-exclusion chromatography using 
PB as eluent. Hapten-to-protein molar ratios were calculated from 40 
absorbance values of the carrier before and after conjugation. 
BSA and OVA conjugates were stored frozen whereas HRP 
tracers were kept at 4 °C with 0.5% (w/v) BSA and 0.01% (w/v) 
thimerosal. 
Generation of polyclonal antibodies  45 
Animal manipulation was performed in compliance with the laws 
and guidelines of the Spanish Ministry of Agriculture, Fisheries, 
and Food and according to European Directive 2010/63 
concerning protection of animals used for scientific purposes. 
Two antisera were generated with each immunogen from two 2 50 
kg female New Zealand white rabbits, which were 
subcutaneously immunized with 0.3 mg of BSA–hapten 
conjugate in 1 mL of a 1:1 mixture of PB and complete Freund’s 
adjuvant. At 21-day intervals, animals were boosted with a 1:1 
emulsion between incomplete Freund’s adjuvant and a PB 55 
solution containing 0.3 mg of the same immunogen. Ten days 
after the fourth injection, whole blood was collected from the ear 
vein of the rabbits and by intracardiac puncture. Blood samples 
were allowed to coagulate overnight at 4 °C; then, the serum was 
separated by centrifugation and immunoglobulins were 60 
precipitated with 1 volume of saturated ammonium sulfate 
solution. This procedure was repeated and the precipitates were 
stored at 4 °C.  
Generation of monoclonal antibodies 
A set of four BALB/c female mice (8–10 weeks old) was 65 
immunized by intraperitoneal injections with each BSA–hapten 
conjugate following standard protocols.49 Briefly, the 
immunization schedule consisted of four injections given at three 
week intervals. Each mouse received 100 µg of conjugate in 200 
µL of a 1:1 mixture of PBS and Freund’s adjuvant (complete for 70 
the first dose and incomplete for the second and third boosts). 
The fourth injection was done without adjuvant four days before 
mouse splenocytes were obtained and fused with myelomas. Cell 
fusion was performed at a 4:1 ratio using 1 mL of PEG 1500 as 
the fusing agent. Fused cells were distributed in 96-well culture 75 
plates at 1.5 × 105 lymphocytes per well in 100 µL of DMEM 
containing 15% (v/v) FBS. Twenty-four hours after plating, 100 
µL of selection medium (DMEM supplemented with HAT) with 
20% (v/v) FBS and 1% (v/v) HFCS was added to each well. 
 Twelve days after cell fusion, hybridoma culture supernatants 80 
were assayed following a sequential double-screening process. 
First, cell cultures were screened by differential indirect 
competitive ELISA with plates coated at 1.0 mg mL−1 OVA–
hapten conjugate, as described by Abad et al.50 Briefly, each 
culture supernatant was analyzed in parallel with and without 85 
competitor (100 nM kresoxim-methyl), and the obtained 
absorbances were compared. The ratio between those assay 
signals was used as the criterion for identification of the best 
clones that secreted antibodies recognizing not only the 
immobilized antigen (positive result) but also the target molecule; 90 
i.e., kresoxim-methyl (competitive result). In a second screening 
assay, culture supernatants from positive and competitive wells, 
and also from those wells that afforded saturated signals in the 
first screening experiment, were re-evaluated by checkerboard 
indirect competitive ELISA as described by Mercader at al.15 95 
Serial dilutions of the supernatant were assayed in the presence of 
kresoxim-methyl at different concentrations (0, 10, and 100 nM), 
using ELISA plates that had been coated with the homologous 
OVA–hapten conjugate at 0.1 and 1.0 µg mL−1. Selected 
hybridomas were cloned twice by limiting dilution in cloning 100 
medium (DMEM containing 20% (v/v) FBS and supplemented 
with HT and 1% (v/v) HFCS). Finally, stable antibody-producing 
clones were expanded and cryopreserved in liquid nitrogen. 
Antibodies were purified from late stationary-phase culture 
supernatants by salting out with ammonium sulfate and 105 
subsequent affinity chromatography, and stored at 4 °C as 
ammonium sulfate precipitates. 
Competitive direct ELISAs 
Immunoassays were performed using the competitive ELISA 
method with immobilized anti-kresoxim-methyl antibody. 110 
Briefly, plates were coated with 100 µL per well of antibody 
dilution in CB by overnight incubation at room temperature. 
After each incubation step, microwells were washed four times 
with washing solution. The competitive reaction was run by 
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addition of 50 µL per well of analyte in PBS plus 50 µL per well 
of HRP–hapten solution in PBST, and incubation during 1 h at 
room temperature. Signal was produced with 100 µL per well of 
freshly prepared enzyme substrate solution. After 10 min at room 
temperature, enzyme activity was stopped upon adding 100 µL 5 
per well of 2.5 M sulfuric acid. Absorbances were immediately 
read at 492 nm with a reference wavelength at 650 nm. 
Standard curves and data analysis 
Standard curves were set up from 10−2 µg L−1 to 104 µg L−1 by 
10-fold serial dilution in PBS. A blank (no kresoxim-methyl) was 10 
also included. Experimental values were fitted to a four-
parameter logistic equation using the SigmaPlot software package 
from SPSS Inc. (Chicago, IL, USA). Antibody affinity was 
estimated as the concentration of kresoxim-methyl at the 
midpoint of the fitted curve, typically corresponding to a 50% 15 
inhibition (IC50) of the maximum absorbance (Amax) if the 
background signal approaches to zero. Polyclonal antibody titer 
was defined as the antiserum dilution that was required in order 
to achieve both an Amax around 1.0 and a minimum IC50 value in 
homologous assays. 20 
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